Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F17%3A10371884" target="_blank" >RIV/00216208:11140/17:10371884 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/17:10371884
Result on the web
<a href="http://dx.doi.org/10.21873/anticanres.12113" target="_blank" >http://dx.doi.org/10.21873/anticanres.12113</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.12113" target="_blank" >10.21873/anticanres.12113</a>
Alternative languages
Result language
angličtina
Original language name
Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature
Original language description
Background/Aim: The prognostic role of microsatellite instability (MSI) in stage II colon cancer patients remains controversial despite the fact that it has been investigated in a number of studies. Hazard ratios differ considerably among these studies. We performed a meta-analysis to define the significance of MSI in this group of patients. Materials and Methods: Studies indexed in PubMed presenting separate data on MSI status and survival outcomes for stage II colon cancer patients have been analyzed using fixed-effect meta-analysis of hazard ratio (HR) according to the method of Peto. Results: Analysis was performed on 19 studies including 5,998 patients. A 47.3% of patients received postoperative chemotherapy and included 52.8% males and 47.2% females. Eight studies included some rectal cancer patients although this cohort was not clearly defined in 3 of these. MSI observed in 20.8% (mean) of patients (median 19.9%). HR for overall survival (OS) of MSI vs. microsatellite stable (MSS) tumors for the entire population: 0.73 (95% confidence interval (CI) = 0.331.65); HR for disease-free survival (DFS): 0.60 (95% CI = 0.271.32). No statistical significant difference was found when studies analyzing MSI with genotyping (MG) and immuno histochemistry (IHC) were compared separately (MG vs. IHC: HR OS 0.45, 95% CI = 0.10-2.05 vs. 0.95, 95% CI = 0.57-1.58; HR DFS 0.51, 95% CI = 0.14-1.85 vs. 0.67, 95% CI = 0.26-1.70). However, numerically MSI determination with genotyping shows significantly lower hazard ratios for both DFS and OS. Separate analysis of studies describing colon cancer patients only showed HR OS 0.72 (95% CI = 0.31-1.71); HR DFS 0.60 (95% CI = 0.27-1.31). Conclusion: No significant relation was found between MSI status and OS or DFS. Routine determination of MSI status to guide postoperative management of stage II colon cancer patients cannot be recommended. New large scale high quality studies are needed to answer this question definitively, since currently analyzed studies vary considerably.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Anticancer Research
ISSN
0250-7005
e-ISSN
—
Volume of the periodical
37
Issue of the periodical within the volume
12
Country of publishing house
GR - GREECE
Number of pages
12
Pages from-to
6563-6574
UT code for WoS article
000417022100008
EID of the result in the Scopus database
2-s2.0-85038129708